Zvinoenderana nemhedzisiro yechikamu chechipiri chechidzidzo, kusanganiswa kweyakajairwa-kutarisira chemotherapy drug azacitidine uye immune checkpoint inhibitor. nivolumab ( nivolumab) yakaratidza kuti chiyero chekupindura uye kudzoka kwevarwere vane kudzokazve kana kuti refractory acute myeloid leukemia ( AML Huwandu hwese hwekupona huri kukurudzira.
Chidzidzo chakatevera varwere makumi manomwe. Mushure mevhareji yemitsara miviri yekurapa, yakadzokororwa AML yakashuma huwandu hwekupindura hwe70% uye yakakwana mhinduro ye2%. Iko kusanganiswa kwemushonga kunonyanya kushanda kuvarwere vasina kumbobvira vagamuchira hypomethylation agents (HMA) senge azacitidine kana decitabine, uye huwandu hwakazara hwevarwere i33%.
Vatsvaguriri vakati masampuro emongo wemapfupa akaunganidzwa pamberi pekurapwa kwakaratidza kuti kuwanda kwekufungidzira kwemafupa CD3 nemaCD8 masero kurapwa kusati kwakwirira. Kunyanya, CD3 inoita kunge ine kukwirisa kwepamusoro uye huwandu hwehuwandu hwekufungidzira mhinduro, zvichiratidza kuti inogona kushandiswa seyakavimbika biomarker yekusarudza varwere veiyi yekubatanidza kurapa. "
Kurapa kunosanganisira intravenous kana subcutaneous jekiseni reazacitidine uye jekiseni rekubaya re nivolumab. Kunyangwe vazhinji varwere vakabudirira kurapwa, 11% yevarwere vachiri nezvakakomba kana zvinogona kutyisidzira hupenyu mhedzisiro. Hupenyu hwese hwevarwere vese hwaive mwedzi 6.3. Kupona kwevarwere vakatanga kudzokazve kwaive mwedzi gumi nematanhatu, yaive yakapetwa kaviri iyo yekupona yakaonekwa neazacitidine yega mune varwere vakafanana muMD Anderson.
Muongorori Daver akataura kuti akakodzera akasarudzika echikamu chechitatu kudzidza kuri kuenderera, uye isu tinotenda kuti kuitiswa kwemakiriniki uye immune biomarkers yekusarudza varwere kunogona kukonzera kumwe kuvandudzwa mune aya marudzi ekurapa muAML.
https://medicalxpress.com/news/2018-11-combination-chemotherapy-immunotherapy-effective-phase.html
